Abstract
We report a case of both lamivudine (LAM) and adefovir dipivoxil (ADV) resistant liver cirrhosis type B. A 47-year-old woman was hospitalized with chronic active hepatitis with cirrhosis type B. Because her serum alanine aminotransferase (ALT) and hepatitis B virus (HBV) DNA level elevated, she was treated with LAM (100 mg/day). Serum ALT and HBV DNA reductions were observed in 4 months. Nine months after the administration of LAM, HBV DNA and ALT levels re-elevated following the appearance of YMDD mutant (YVDD+YIDD). Additional treatment with ADV (10 mg/day) was commenced, and her serum ALT was decreased during 3 months. However, breakthrough phenomena were observed again 26 months after ADV treatment. This is the first reported case of breakthrough hepatitis associated with both LAM-and ADV-resistant HBV.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
